Increlex (Mecasermin)

Mecasermin is a recombinant form of human IGF‑1 that binds to IGF‑1 receptors on target tissues. This binding activates intracellular signaling cascades that promote cell proliferation, protein synthesis, and bone growth, thereby supporting normal height development in patients lacking adequate endogenous IGF‑1.

The dose of Increlex is individualized. A qualified prescriber determines the appropriate amount based on the patient’s age, weight, IGF‑1 levels, and response to therapy. Dosing is typically adjusted over time to achieve optimal growth outcomes while minimizing adverse effects.

The safety of Mecasermin in pregnant or nursing women has not been established. It is classified as pregnancy category unknown, and the drug should only be used if the potential benefit justifies the potential risk to the fetus or infant. Consultation with a specialist is essential.

To request Increlex, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details, and necessary import documentation.

Increlex differs from conventional recombinant growth‑hormone products because it directly replaces IGF‑1 rather than stimulating its production. It is the preferred option for patients with primary IGF‑1 deficiency or GH‑gene deletions, whereas GH therapy is used when the GH‑IGF‑1 axis is intact.

Increlex must be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. If the product reaches room temperature, it should be used promptly and not re‑refrigerated.

Increlex is given as a subcutaneous injection, usually into the thigh, abdomen, or upper arm. The injection site should be rotated to reduce local irritation. Administration is performed by a healthcare professional or a trained caregiver following aseptic technique.

Serious risks include severe hypoglycemia, intracranial hypertension, allergic reactions such as anaphylaxis, and potential acceleration of tumor growth in patients with a history of malignancy. Prompt medical evaluation is required if any of these events are suspected.

Increlex is contraindicated in patients with known hypersensitivity to Mecasermin or any excipients, those with active malignancies, or individuals who have experienced severe hypoglycemia that cannot be managed. It should also be avoided in patients with uncontrolled intracranial hypertension.